» Articles » PMID: 35816360

Inflammation Accelerates BCR-ABL1+ B-ALL Development Through Upregulation of AID

Overview
Journal Blood Adv
Specialty Hematology
Date 2022 Jul 11
PMID 35816360
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation contributes to the initiation and disease progression of several lymphoid malignancies. BCR-ABL1-positive B-cell acute lymphoblastic leukemia (BCR-ABL1+ B-ALL) is triggered by the malignant cloning of immature B cells promoted by the BCR-ABL1 fusion gene. However, it is unclear whether the mechanism driving the disease progression of BCR-ABL1+ B-ALL involves inflammatory stimulation. Here, we evaluate BCR-ABL1+ B-ALL cells' response to inflammatory stimuli lipopolysaccharide (LPS) in vitro and in vivo. The results indicate that LPS promotes cell growth and genomic instability in cultured BCR-ABL1+ B-ALL cells and accelerates the BCR-ABL1+ B-ALL development in a mouse model. We show that the LPS-induced upregulation of activation-induced deaminase (AID) is required for the cell growth and disease progression of BCR-ABL1+ B-ALL. Moreover, AID modulates the expression of various genes that are dominated by suppressing apoptosis genes and upregulating DNA damage-repair genes. These genes lead to facilitation for BCR-ABL1+ B-ALL progression. The heat shock protein 90 (Hsp90) inhibitors significantly reduce AID protein level and delay the disease progression of BCR-ABL1+ B-ALL upon inflammatory stimulation. The present data demonstrate the causative role of AID in the development and progression of BCR-ABL1+ B-ALL during inflammation, thus highlighting potential therapeutic targets.

Citing Articles

B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Mimicking Fibrosing Mediastinitis: A Case Report and Diagnostic Insight.

Kitamura A, Yanagi S, Shide K, Sato Y, Kamiunten A, Yamanari Y Am J Case Rep. 2024; 25:e945804.

PMID: 39736074 PMC: 11694771. DOI: 10.12659/AJCR.945804.


Inflammation as a driver of hematological malignancies.

Saluja S, Bansal I, Bhardwaj R, Beg M, Palanichamy J Front Oncol. 2024; 14:1347402.

PMID: 38571491 PMC: 10987768. DOI: 10.3389/fonc.2024.1347402.


Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.

Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu J, Gebing P Cell Death Dis. 2023; 14(12):799.

PMID: 38057328 PMC: 10700369. DOI: 10.1038/s41419-023-06337-3.


Prognostic Impact of Copy Number Alterations' Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy.

Libura M, Karabin K, Tyrna P, Czyz A, Makuch-Lasica H, Jazwiec B Cancers (Basel). 2023; 15(22).

PMID: 38001691 PMC: 10670434. DOI: 10.3390/cancers15225431.

References
1.
Heinaniemi M, Vuorenmaa T, Teppo S, Kaikkonen M, Bouvy-Liivrand M, Mehtonen J . Transcription-coupled genetic instability marks acute lymphoblastic leukemia structural variation hotspots. Elife. 2016; 5. PMC: 4951197. DOI: 10.7554/eLife.13087. View

2.
Araki A, Jin L, Nara H, Takeda Y, Nemoto N, Gazi M . IL-21 Enhances the Development of Colitis-Associated Colon Cancer: Possible Involvement of Activation-Induced Cytidine Deaminase Expression. J Immunol. 2019; 202(11):3326-3333. DOI: 10.4049/jimmunol.1800550. View

3.
Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5(3):172-83. DOI: 10.1038/nrc1567. View

4.
Mouw K, Goldberg M, Konstantinopoulos P, DAndrea A . DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017; 7(7):675-693. PMC: 5659200. DOI: 10.1158/2159-8290.CD-17-0226. View

5.
Smith V, Sausville E, Camalier R, Fiebig H, Burger A . Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol. 2005; 56(2):126-37. DOI: 10.1007/s00280-004-0947-2. View